Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Total Assets

Latest as of March 2026: €89.76 Billion EUR ≈ $104.94 Billion USD

Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) holds total assets worth €89.76 Billion EUR (≈ $104.94 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Guangzhou Baiyunshan Pharmaceutical Hold (GU5) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Total Assets Trend (2013–2025)

This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total assets have evolved over time, based on quarterly financial data. Explore GU5 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Asset Composition Analysis

Current Asset Composition (December 2025)

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total assets of €89.76 Billion consist of 72.8% current assets and 27.2% non-current assets.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 17.7%
Accounts Receivable €16.85 Billion 19.9%
Inventory €13.14 Billion 15.6%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €3.19 Billion 3.8%
Goodwill €834.09 Million 1.0%

Asset Composition Trend (2013–2025)

This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Guangzhou Baiyunshan Pharmaceutical Hold worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's current assets represent 72.8% of total assets in 2025, an increase from 59.6% in 2013.
  • Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, up from 15.9% in 2013.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2013.
  • Asset Diversification: The largest asset category is accounts receivable at 19.9% of total assets.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Total Assets

Key competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited based on total assets are shown below.

Company Country Total Assets
China National Medicines Corp Ltd
SHG:600511
China CN¥35.13 Billion
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
China CN¥21.18 Billion
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
Brazil R$5.64 Billion
China National Accord Medicines Corp Ltd
SHE:200028
China HK$49.12 Billion
Sigma Healthcare Ltd
AU:SIG
Australia AU$8.74 Billion
Ebos Group Ltd
AU:EBO
Australia AU$8.80 Billion
Paragon Care Ltd
AU:PGC
Australia AU$1.31 Billion
Mayne Pharma Group Ltd
AU:MYX
Australia AU$1.01 Billion

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.60 1.54 1.64
Quick Ratio 1.29 1.24 1.37
Cash Ratio 0.00 0.00 0.00
Working Capital €24.30 Billion €19.56 Billion €19.70 Billion

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Advanced Valuation Insights

This section examines the relationship between Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.59
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 3.5%
Total Assets €84.51 Billion
Market Capitalization $413.91 Million USD

Valuation Analysis

Below Book Valuation: The market values Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)

The table below shows the annual total assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025.

Year Total Assets Change
2025-12-31 €84.51 Billion
≈ $98.80 Billion
+3.46%
2024-12-31 €81.68 Billion
≈ $95.50 Billion
+3.94%
2023-12-31 €78.59 Billion
≈ $91.88 Billion
+5.25%
2022-12-31 €74.67 Billion
≈ $87.29 Billion
+12.93%
2021-12-31 €66.12 Billion
≈ $77.30 Billion
+10.64%
2020-12-31 €59.76 Billion
≈ $69.87 Billion
+5.04%
2019-12-31 €56.89 Billion
≈ $66.51 Billion
+10.51%
2018-12-31 €51.48 Billion
≈ $60.19 Billion
+81.82%
2017-12-31 €28.31 Billion
≈ $33.10 Billion
+9.34%
2016-12-31 €25.90 Billion
≈ $30.28 Billion
+63.18%
2015-12-31 €15.87 Billion
≈ $18.55 Billion
+11.24%
2014-12-31 €14.27 Billion
≈ $16.68 Billion
+16.47%
2013-12-31 €12.25 Billion
≈ $14.32 Billion
--

About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

F:GU5 Germany Medical Distribution
Market Cap
$413.91 Million
€354.04 Million EUR
Market Cap Rank
#13365 Global
#1386 in Germany
Share Price
€1.61
Change (1 day)
+0.00%
52-Week Range
€1.61 - €2.30
All Time High
€2.30
About

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more